610797-49-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-4-fluoro-2-isopropoxybenzene is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic applications, contributing to the development of novel drugs and treatments.

Upstream product

• 75-26-3 isopropyl bromide 
• 147460-41-1 2-bromo-5-fluorophenol 
• 75-30-9 2-iodo-propane 
• 348-57-2 2,4-difluorobromobenzene 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 910605-64-0 4-(4-fluoro-2-isopropoxy-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 861928-70-3 1-bromo-2-isopropoxy-4-benzylthiobenzene 
• 861928-65-6 1-bromo-2-isopropoxy-4-methylthio-benzene 
• 910605-68-4 4-[4-(4-fluoro-2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine 
• 910605-67-3 {4-[4-(4-fluoro-2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 910605-66-2 4-(4-fluoro-2-isopropoxy-phenyl)-piperidine 
• 910605-65-1 4-(4-fluoro-2-isopropoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 946605-67-0 C₁₉H₂₆FNO₃ 

Relevant academic research and scientific papers

Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols

In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzen

Regioselectivity of fluorine substitution by alkoxides on unsymmetrical difluoroarenes

An efficient approach to unsymmetrical halogenated resorcinol diethers has been developed. This synthesis consists of two subsequent nucleophilic aromatic substitutions (SNAr) of unsymmetrical difluoroarenes by alkoxides. The novelty of this ap

(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Although α1 adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selec

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma. X16065 PCT - -

Ruthenium olefin metathesis catalysts with modified styrene ethers: Influence of steric and electronic effects

A series of olefin metathesis catalysts with modified isopropoxybenzylidene ligands were synthesised, and the effects of ligands on the rate of metathesis investigated. Increased steric hinderance ortho to the isopropoxy group enhanced reaction rates. In the case of N-heterocyclic carbene complexes, decreasing electron density at both the chelating oxygen atom and the Ru=C bond accelerated reaction rates appreciably. Catalysts containing a tricyclohexylphosphane ligand, followed the same trend with regard to benzylidene electrophilicity, while higher electron density at oxygen enhanced reaction rates.